Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVICE: KESONOTIDE in Solid Tumours
NCT06926075Phase 2Recruiting
- Sponsor
- Filamon Limited
- Start
- Nov 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of kesonotide in solid tumor, prostate cancer (PCa), breast cancer and 5 more (2 arms), sponsored by Filamon Limited. Primary endpoints: Incidence of Serious Adverse Events at 21 days, Treatment Emergent Adverse Effects at 21 days and 6 more. Started Nov 2025; status: recruiting.
02
Drugs
kesonotide
03
Conditions
solid tumorprostate cancer (PCa)breast cancerlung cancerovarian cancer
Beyond the preview
Go deeper on NCT06926075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926075.